Indivior Pharmaceuticals (INDV) Current Taxes (2021 - 2026)

Indivior Pharmaceuticals' Current Taxes history runs 6 years deep, the most recent figure standing at $26.0 million for Q1 2026.

• On a quarterly basis, Current Taxes rose 116.67% year-over-year to $26.0 million in Q1 2026; TTM through Mar 2026 was $26.0 million, a 116.67% increase from a year earlier, with the FY2025 full-year figure at $2.0 million, down 71.43% from the prior year.
• Current Taxes rose to $26.0 million in Q1 2026 per INDV's latest filing, from $2.0 million in the prior quarter.
• Across five years, Current Taxes topped out at $26.0 million in Q1 2026 and bottomed at $2.0 million in Q4 2025.
• The 5-year median for Current Taxes is $8.5 million (2022), against an average of $10.6 million.
• Across the five-year window, Current Taxes plunged 71.43% in 2025 and soared 116.67% in 2026, its largest moves.
• Year by year, Current Taxes stood at $9.0 million in 2022, then decreased by 11.11% to $8.0 million in 2023, then decreased by 12.5% to $7.0 million in 2024, then plunged by 71.43% to $2.0 million in 2025, then jumped by 1200.0% to $26.0 million in 2026.
• Per Business Quant, the three latest INDV Current Taxes figures stand at $26.0 million (Q1 2026), $2.0 million (Q4 2025), and $4.0 million (Q3 2025).